1/15
08:31 am
imtx
Institutional investors own a significant stake of 38% in Immatics N.V. (NASDAQ:IMTX) [Yahoo! Finance]
Low
Report
Institutional investors own a significant stake of 38% in Immatics N.V. (NASDAQ:IMTX) [Yahoo! Finance]
1/11
01:03 am
imtx
Low
Report
1/3
01:06 am
imtx
Medium
Report
12/25
12:11 am
imtx
Immatics: PRAME Leader's Transition To Commercial Reality [Seeking Alpha]
Low
Report
Immatics: PRAME Leader's Transition To Commercial Reality [Seeking Alpha]
12/11
07:31 am
imtx
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress [Yahoo! Finance]
Low
Report
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress [Yahoo! Finance]
12/11
07:00 am
imtx
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
Low
Report
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
12/6
09:21 pm
imtx
Immatics (NasdaqCM:IMTX) Valuation Check After Follow-On Share Offering Announcement [Yahoo! Finance]
Low
Report
Immatics (NasdaqCM:IMTX) Valuation Check After Follow-On Share Offering Announcement [Yahoo! Finance]
12/5
06:24 am
imtx
Biotech Immatics to raise $125M through ordinary share offering [Seeking Alpha]
Medium
Report
Biotech Immatics to raise $125M through ordinary share offering [Seeking Alpha]
12/5
06:13 am
imtx
Immatics Announces $125 Million Underwritten Offering [Yahoo! Finance]
Medium
Report
Immatics Announces $125 Million Underwritten Offering [Yahoo! Finance]
12/5
06:00 am
imtx
Immatics Announces $125 Million Underwritten Offering
High
Report
Immatics Announces $125 Million Underwritten Offering
12/4
08:12 am
imtx
Immatics (NASDAQ:IMTX) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
High
Report
Immatics (NASDAQ:IMTX) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
11/24
11:04 am
imtx
Immatics (NASDAQ:IMTX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $25.00 price target on the stock.
Low
Report
Immatics (NASDAQ:IMTX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $25.00 price target on the stock.
11/19
09:37 am
imtx
Immatics (NASDAQ:IMTX) had its price target raised by analysts at Mizuho from $19.00 to $23.00. They now have an "outperform" rating on the stock.
Low
Report
Immatics (NASDAQ:IMTX) had its price target raised by analysts at Mizuho from $19.00 to $23.00. They now have an "outperform" rating on the stock.
11/18
09:34 am
imtx
Immatics (NASDAQ:IMTX) had its price target raised by analysts at Guggenheim from $16.00 to $19.00. They now have a "buy" rating on the stock.
Medium
Report
Immatics (NASDAQ:IMTX) had its price target raised by analysts at Guggenheim from $16.00 to $19.00. They now have a "buy" rating on the stock.
11/18
06:19 am
imtx
Should Immatics' (IMTX) New Clinical Data on IMA402 and IMA401 Prompt Fresh Investor Attention? [Yahoo! Finance]
Medium
Report
Should Immatics' (IMTX) New Clinical Data on IMA402 and IMA401 Prompt Fresh Investor Attention? [Yahoo! Finance]
11/17
07:22 am
imtx
Immatics Announces Third Quarter 2025 Financial Results and Business Update [Yahoo! Finance]
Medium
Report
Immatics Announces Third Quarter 2025 Financial Results and Business Update [Yahoo! Finance]
11/17
07:00 am
imtx
Immatics Announces Third Quarter 2025 Financial Results and Business Update
Medium
Report
Immatics Announces Third Quarter 2025 Financial Results and Business Update
11/12
07:00 am
imtx
Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps
High
Report
Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps
10/29
09:03 am
imtx
Immatics (NASDAQ:IMTX) was given a new $19.00 price target on by analysts at Mizuho.
Low
Report
Immatics (NASDAQ:IMTX) was given a new $19.00 price target on by analysts at Mizuho.
10/27
07:00 am
imtx
Immatics Appoints Amie Krause as Chief People Officer
Medium
Report
Immatics Appoints Amie Krause as Chief People Officer